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Abstract
Introduction Breast cancers are traditionally divided into
hormone-receptor positive and negative cases. This
classification helps to guide patient management. However, a
subgroup of hormone-receptor positive patients relapse
irrespective of hormonal therapy. Gene expression profiling has
classified breast tumours into five major subtypes with
significant different outcome. The two luminal subtypes, A and
B, show high expression of ESR1, GATA3 and FOXA1 genes.
Prognostic biomarkers for oestrogen receptor (ER)-positive
cases include progesterone receptor (PR) and androgen
receptor (AR), and proteins related to proliferation or apoptotic
resistance. The aim of this study was to identify the best
predictors of success of hormonal therapy.
Methods By immunohistochemistry we studied 10 markers in a
consecutive series of 832 cases of breast carcinoma treated at
the Paoli-Calmettes Institute from 1990 to 2002 and deposited
onto tissue microarrays (TMA). These markers were luminal-
related markers ER, PR, AR, FOXA1 and GATA3 transcription
factors, proliferation-related Ki67 and CCND1, ERBB2, anti-
apoptotic BCL2 and P53. We also measured vascular
peritumoural invasion (VPI), size, grade and lymph node
involvement. For 143 cases, gene expression profiles were
available. Adjuvant chemotherapy and hormonal therapy were
given to high- and low-risk patients, respectively. The 162
events observed and taken into account were metastases.
Results Molecular expression of the 10 parameters and subtype
with ER status were strongly correlated. Of the 67 luminal A
cases of this series, 63 were ER-positive. Multivariate analyses
showed the highly significant prognostic value of VPI (hazard
ratio (HR) = 2.47), Ki67 (HR = 2.9), P53 (HR = 2.9) and GATA3
(HR = 0.5) for the 240 patients who received hormonal therapy.
Conclusions A panel of three antibodies (Ki67, P53 and
GATA3) associated with VPI can significantly improve the
traditional prognosticators in predicting outcome for ER-positive
breast cancer patients receiving hormonal therapy.
Introduction
The traditional division of breast cancers into hormone recep-
tor positive and negative cases helps to guide patient manage-
ment. However, a subgroup of hormone receptor-positive
patients relapse irrespective of standard hormonal therapy.
Gene expression profiling has classified breast tumours into
five major molecular subtypes with different outcomes. The
two luminal subtypes, A and B, express the ESR1, GATA3 and
FOXA1 genes [1].
Compared with luminal A, luminal B tumours have a poor prog-
nosis [1-3]. However, there are few indicators to determine if
AR: androgen receptor; CI: confidence interval; ER: oestrogen receptor; H&E: haematoxylin and eosin; HR: hazard ratio; MFS: metastasis-free sur-
vival; NSABP: National Surgical Adjuvant Breast and Bowel Project; PCR: polymerase chain reaction; PR: progesterone receptor; QS: quick score; 
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the response to hormonal therapy is different between A and
B subtypes. In a previous study we validated a non-linear algo-
rithm including six immunohistochemical markers on tissue
microarrays (TMA): oestrogen receptor (ER), progesterone
receptor (PR), ERBB2, BCL2, P53 and MYC [4]. This algo-
rithm had strong prognostic value in ER-positive patients with
or without hormonal therapy. The difference between luminal
A and B was not investigated in this study. In another study we
showed that the subset of patients with luminal A tumours,
called Ab, which express mitotic kinases had a poorer progno-
sis than the majority that do not express these kinases [5]. This
subset with high kinase score had a prognosis close to luminal
B tumours. In fact, luminal Ab resemble luminal B tumours;
they are distinguished only because the lists of genes used in
gene expression analyses to identify subtypes are not accu-
rate enough and because luminality reflects a continuum from
poorly differentiated, highly proliferative (luminal B) to well-dif-
ferentiated, poorly proliferative (luminal Aa).
The prognostic distinction between luminal Aa and Ab sug-
gest that grade and P53 are also involved but the kinase score
was associated with the highest hazard ratio (HR). In the
absence of reliable antibodies the kinase score is difficult to
implement in a routine setting. We therefore searched for eas-
ily identifiable factors that could be associated with the prog-
nosis of patients receiving hormonal therapy for the different
luminal subtypes.
P53 mutation is generally associated with basal breast cancer.
However, we demonstrated its impact in luminal cases [5].
P53 expression observed in BRCA1 luminal cases corre-
spond to a true mutation in only four of seven cases [6]. This
suggests that P53 expression could be associated with prolif-
eration in luminal cases independent of mutation.
Quantitative ER status is correlated with a strong response to
hormonal therapy. PR, GATA3 and FOXA1, and proteins
related to proliferation or apoptotic resistance such as BCL2
could also influence hormonal response. The transcription fac-
tor GATA3 is a defining marker of the luminal subtypes.
GATA3 has an essential role in the morphogenesis of the
mammary gland and actively maintains luminal epithelial differ-
entiation [7]. We demonstrated a good correlation between
GATA3 gene and protein expression [2]. A recent meta-analy-
sis [7] showed that both ER-alpha and GATA3 are coex-
pressed with ER-alpha-associated genes such as PS2/TFF1,
TFF3, FOXA1, BCL2, ERBB4, XBP1, NRIP, IL6ST, Keratin 18
and cyclin D1/CCND1. The transcription factor FOXA1 is a
downstream target of GATA3 in the mammary gland. FOXA1
expression is associated with that of ER, PR and androgen
receptor (AR) [8-10] and with a better survival. FOXA1 binds
to chromatinised DNA, opens the chromatin and enhances
binding of ER-alpha. Thus, a network comprising GATA3,
FOXA1, ER-alpha and oestrogen constitutes a major prolifer-
ation and survival signal for luminal A breast cancer [11].
Many human breast cancers express AR. A recent study of AR
on formalin-fixed, paraffin-embedded archival specimens of
200 cases of breast cancer showed that 60% of invasive car-
cinoma and 82% of ductal carcinoma in situ were AR-positive
[12]. The great majority of well-differentiated carcinomas were
both AR and ER-positive. In contrast, 39% of poorly-differenti-
ated carcinomas were ER-negative but AR-positive. The clini-
cal value of AR expression is unclear. However, AR expression
was strongly correlated with ER in a series of 842 breast car-
cinomas [13]. Few studies suggest the impact of AR on the
response to hormonal therapy [14].
Finally, a recent meta–analysis confirmed that BCL2 has an
independent prognostic impact [15]. However, no prospective
study has shown the predictive impact of BCL2 expression in
ER-positive cases.
The aim of our study was to identify the prognosis of patients
receiving hormonal therapy among histoclinical and immuno-
histochemical factors.
Materials and methods
Patients
We studied a consecutive series of 832 tumours with early
(stage I, II or III) breast cancer treated in our institution
between October 1987 and December 2001 and with suffi-
cient cancer tissue available for inclusion in TMA. The stage of
disease was defined according to the tumour node metastasis
(TNM) classification. Tumours were all invasive adenocarcino-
mas. The patients were treated according to guidelines used
in our institution: all had primary surgery that included com-
plete resection of the tumour (modified radical mastectomy in
28% of cases, lumpectomy in 72%) and axillary lymph node
dissection; 96% were treated with breast-conservative sur-
gery received adjuvant local-regional radiotherapy; 51.3%
were given adjuvant chemotherapy (anthracyclin-based regi-
men in most cases); 56.5% received adjuvant hormone treat-
ment (tamoxifen in most cases) and 54.9% of these received
adjuvant chemotherapy. After completion of treatment, the
patients were evaluated at least twice a year for the first five
years and at least annually thereafter. The median follow-up
was 86 months after diagnosis; 162 patients experienced
metastatic relapse as a first event (local recurrence was not
taken into account as first event). The five-year metastasis-free
survival (MFS) rate was 83.2% (95% confidence interval (CI)
= 80.4 to 85.8). The experimental part of this study concerning
paraffin-embedded samples was completed before informed
consent was necessary but was approved and executed in
compliance with our institutional review board. Each sample
was assigned an anonymous unique identification that was
linked to an anonymous clinical board approved data base
containing follow-up information. The study was performed
with the intent of benefiting treatment planning in future
patients.Available online http://breast-cancer-research.com/content/11/2/R23
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Breast cancer samples
Tissues were collected from 143 patients with invasive aden-
ocarcinoma who underwent initial surgery at the Institut Paoli-
Calmettes (Marseilles, France). Each patient gave written
informed consent. Samples were macro-dissected and frozen
in liquid nitrogen within 30 minutes of removal.
DNA and RNA extraction
Nucleic acids were extracted from frozen samples by using
guanidium isothiocyanate and cesium chloride gradient, as
previously described [16]. RNA integrity was controlled on the
Agilent Bioanalyzer (Agilent Technologies, Massy, France).
Gene expression profiling with DNA microarrays
Gene expression was analysed in 143 breast cancer samples
and four normal breast samples with Affymetrix U133 Plus 2.0
human oligonucleotide microarrays (Affymetrix Santa Clara,
CA, USA). Preparation of c-RNA, hybridisations, washes and
detection were performed as recommended by the supplier.
For each sample, synthesis of the first-strand c-DNA was done
from 3 μg total RNA by T7-oligo(dT) priming, followed by sec-
ond-strand cDNA synthesis. After purification, in vitro tran-
scription associated with amplification generated cRNA-
containing biotinylated pseudouridine. Biotinylated cRNA was
purified, quantified and chemically fragmented (95°C for 35
minutes), then hybridised to microarrays in 200 μL hybridisa-
tion buffer at 45°C for 16 hours. Automated washes and stain-
ing with streptavidin-phycoerythrin were performed as
recommended. Double signal amplification was achieved by
biotinylated antistreptavidin antibody with goat-IgG blocking
antibody. Scanning was performed with Affymetrix GeneArray
scanner and quantification with Affymetrix GCOS software.
Gene expression data analysis
Affymetrix data were analysed by the Robust Multichip Aver-
age method in R using Bioconductor and associated pack-
ages [17]. The Robust Multichip Average performed
background adjustment, quantile normalisation and summari-
sation of 11 oligonucleotides per gene. Before analysis, a fil-
tering process removed the genes with low and poorly
measured expression, as defined by an expression value infe-
rior to 100 units in all breast cancer tissue and normal tissue
samples, from the dataset. All data was then log2-transformed
for display and analysis.
Basal and luminal breast cancers were distinguished by the
differential expression of clusters of genes. Sub-classification
of the luminal cases was done as previously described [5].
Kinase gene expression identified two subgroups of luminal A
breast cancers, that is luminal Aa and Ab.
Tissue microarrays construction and 
immunohistochemistry
TMAs were prepared as previously described [18] from forma-
lin-fixed and paraffin-embedded tissue. For each tumour, three
representative areas were selected from a H&E-safran-stained
section of a donor block. Core cylinders with a diameter of 0.6
mm each were punched from each of these areas and depos-
ited into three separate recipient paraffin blocks using a spe-
cific arraying device (Alphelys, Plaisir, France).
Immunohistochemistry of 5 μmm TMA sections was per-
formed as previously described using Dako LSABR2 Kit in the
autoimmunostainer (Dako Autostainer, Glostrup, Denmark).
Sections were deparaffinised in Histolemon (Carlo Erba Rea-
genti, Rodano, Italy) and rehydrated in graded ethanol solu-
tions. Results were evaluated under a light microscope by two
pathologists (EC-J, JJ) and scored by the quick score (QS)
[19]. The QS was used to combine the impact of the percent-
age and the intensity of the immunostaining. QS multiplies the
percentage by the intensity and represents a range of 0 to
300. For each antibody, a sample was considered as positive
when the QS was strictly superior to 0. However, the Ki67 sta-
tus was expressed in terms of percentage of positive cells,
with a threshold of 20% of positive cells. The ERBB2 status
was evaluated with the Dako scale (HercepTest kit scoring
guidelines, DakoCytomation, Copenhagen, Denmark). The
level of 3+ was considered as positive and all 2+ cases were
evaluated by chromogen in situ hybridisation (only the case
with a ratio higher than 2.2 were considered as positive).
For each tumour, the mean of the score of a minimum of two
core biopsies was calculated. The list of antibodies used is
given in Table 1.
Statistical analysis
Survival rates were estimated by using the Kaplan-Meier
method [20]. The endpoint was the MFS, which was defined
as the time from the date of breast cancer diagnosis until the
date of the first distant relapse. Patients without relapse were
censored at the time of last follow-up. Survival analysis was
computed with a stratification on treatment by chemotherapy.
Relative risks of metastasis according to the baseline factors
were estimated by using the Cox proportional-hazards regres-
sion models [21] in univariate and multivariate analyses. In uni-
variate analysis, differences in MFS were analysed by the Log-
Rank test. Factors with a P value less than 0.15 in univariate
analysis were included in the multivariate analysis, with a back-
ward selection of variable procedure to minimise the Akaike
information criterion [22]. Results are presented as mean
(95% CI). Statistical analyses were performed with the
R.2.7.1. Statistical language [23].
Results
Correlation between molecular subtype and oestrogen 
receptor immunohistochemical status
A total of 135 of the 143 cases showed good-quality RNA and
profiles. The correlation between expression of each parame-
ter between microarrays and QS was excellent and highly sig-Breast Cancer Research    Vol 11 No 2    Jacquemier et al.
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nificant (Table 2). The lowest level of the Rho coefficient was
observed for Ki67, P53 and ERBB2.
The frequency of the different subtypes was: 25% basal, 12%
ERBB2, 46% luminal A (68.1%% Aa and 31.8%% Ab), 2%
luminal B and 9% normal-like. Molecular subtype and ER sta-
tus were strongly correlated. Only 8% of basal breast cancers
were ER-positive for 23.5% of ERBB2, 95.5% of luminal A,
100% of luminal B and 53.8% of normal-like breast cancers
(Table 3).
Univariate and multivariate analyses of survival
We studied the impact of 16 histoclinical and immunohisto-
chemical factors on disease-free survival. Hormonal therapy,
size of the lesion, histoprognostic grade, vascular peritumoural
invasion (VPI), ER, BCL2, GATA3, Ki67 and P53 had signifi-
cant impact (Table 4). Only age, CCND1, PR, FOXA1 did not
have any significant value in MFS.
For ERBB2 there was a significant difference in terms of dis-
ease-free survival at 60 months with 83.7% for the negative
cases and 69.1% for the 3+ cases and amplified 2+ (P =
0.017). However, when the analysis was stratified on the pres-
ence or not of chemotherapy, no significant difference
between the two groups was noted.
Eight factors were retained by the multivariate analysis includ-
ing histopronostic grade, axillary lymph node invasion, VPI,
size, then Ki67, P53, BCL2 and hormonal therapy (Table 5).
Molecular subtype and oestrogen receptor positivity
In the restricted ER-positive population studied by gene
expression profiling we observed that 67 of 81 (86.4%) were
luminal cases (Table 6). There was no difference in ER-positiv-
ity level (with a cut off QS of 120) between luminal Aa (18 of
43 above 120, 41.8%) and luminal Ab (8 of 21 above 120,
38%) cases. However, a significant difference was observed
for proliferation: luminal Ab showed a higher grade (P  =
4.710; Table 6) and a higher Ki67 index (P = 0.02) than lumi-
Table 1
Immunohistochemical antibodies used to characterize the luminal cases
Protein (Clone) Antibody Origin Clone Pre-treatment Dilution Location of staining Normal
Androgen receptor
(AR)
mmb Dako 4AR441 PH9
Target retrieval solution
(98°C, 40 min)
1/50° nucleus +
BCL2 mmb Dako 124 Citrate* 1/100° cytoplasm +
CyclinD1
CCND1
mmb Labvision SP4 EDTA* prediluted nucleus +
ERBB2 mmb Dako
Herceptest Ltd
AO485 Target retrieval * 1/500 membrane -
Estrogen receptor 
(ER)
mmb Novocastra laboratories 
Ltd
6F11.2 Target retrieval * 1/60 nucleus +
FOXA1 mmb AbNova 2D7 Citrate* 1/250 nucleus +
GATA3 mmb Santacruz HG3-31 Citrate* 1/100° nucleus +
P53 mmb Beckmann DO-1 Citrate* 1/4 nucleus -
Progesterone
receptor (PR)
mmb Dako PFR 636 Target retrival * 1/80 nucleus +
Ki67 mmb Dako KI-67 Target retrieval solution 
*
1/100 nuclear +
+ = positive expression, - = negative expression.
The asterisk symbols mean that it is a buffer solution.
Table 2
Correlation between expression in microarray and quick score of the ten markers analysed
Spearman correlation test AR BCL2 CCND1 ERBB2 FOXA1 GATA3 KI67 P53 ER PR
Rho * 0.49 0.56 0.43 0.28 0.58 0.64 0.32 0.30 0.73 0.69
P < 0.0001 < 0.0001 < 0.0001 0.00067 < 0.0001 < 0.0001 0.00018 0.00023 < 0.0001 < 0.0001
Rho test the non nullity of the correlation (Spearman test). The level of signification is expressed by the P value.Available online http://breast-cancer-research.com/content/11/2/R23
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nal Aa. The three luminal B were ER-positive (the percentage
of ER-positive cells was below 5% for two cases) but grade 3.
Two were positive for P53.
One-third of the luminal A were Ab (31.8%) and two-thirds
(68.1%) were luminal Aa cases. The four ERBB2-subtype
cases were ER-positive but the level of ER expression was
lower than the median value of QS 120; all the cases were
grade 3 and PR-negative. The seven normal-like cases were
grade 1 (n = 5) or 2 (n = 2) and four showed a low level of ER
protein expression.
Markers and survival
We then restricted the study to the ER-positive cases treated
by hormonal therapy (n = 384). Subtype status was available
for only a small series of these cases (n = 43). MFS was dif-
ferent between luminal Aa and Ab cases (P = 0.042; Figure
1). Of the 14 factors studied in univariate analysis (Table 7)
only 6 showed a different distribution: size, grade, VPI, lymph
node invasion, GATA3 and Ki67. Oestrogen-related proteins
such as FOXA1 and AR had no significant impact whatever
their quantitative value. The ER and PR level of expression had
no significant MFS value in univariate analysis. The multivariate
analysis in terms of MFS retained four factors: VPI, Ki67, P53
and GATA3 (Table 8).
Discussion
The aim of this study was to study the expression of proteins
corresponding to genes identified by gene expression profiling
to be associated with luminal cases and to determine their
impact on the response of patients to hormonal therapy. Due
to experimental conditions (e.g. quality of the antibodies), the
analysis was limited to 10 proteins. We were able to identify a
score combining four factors able to predict the evolution of
the luminal cases treated with adjuvant hormonal tamoxifen
therapy.
Molecular subtypes and prognosis
Grossly, our 135 subtyped cases showed a similar distribution
of subtypes as found in previous studies [1,2,24]. Our series
contained 25% of basal cases, which is within a published
range of 17 to 37%. The number of ERBB2 subtype (12%)
was slightly higher than in most series. In contrast, the 45%
frequency of luminal A was high and the proportion of luminal
B was low.
In a previous study [5] we focused on the kinome of luminal A
breast cancers. The breast cancer kinome differs between
basal and luminal A cases. Within luminal A cases, it allowed
the identification of luminal Aa and Ab. Here, we have con-
firmed the difference in outcome between luminal Aa and Ab
by using immunohistochemistry on 43 luminal A cases treated
by tamoxifen. The difference between luminal Aa and Ab was
due to proliferative factors translated by a higher grade and
Ki67 index in luminal Ab than in luminal Aa cases. The fact that
a difference could be seen already with a small series sug-
gests the importance of proliferation to distinguish outcome in
ER-positive cases whatever their percentage of ER-positive
cells.
Prognosis and hormonal therapy in ER-positive cases
Four factors, VPI, GATA3, P53 and Ki67, were retained by the
multivariate analysis.
Two parameters were added in the 9th St Gallen meeting
compared with the 8th edition: ERBB2 status and VPI. The
volume of data published in the past few years provides com-
pelling evidence for the importance of VPI [25] but the specific
impact on luminal cases had never been described. A meta-
analysis of microarray data revealed the importance of GATA3
[26]. Its expression in 10-year follow-up [27] demonstrates
that its protective effect is more pronounced in patients who
received tamoxifen. We showed the prognostic impact of P53
in two previous studies of luminal cases [4,5]. Ki67 higher than
20% is one of the parameters able to distinguish luminal A
from luminal B [28] but its specific prognostic impact in lumi-
nal cases had not been described.
An important question is whether the combination of VPI,
GATA3, P53 and Ki67 predicts pure prognosis or responsive-
ness to endocrine therapy or both. Few studies using profiling
of ER-positive breast cancers treated by tamoxifen have estab-
lished a signature able to predict the prognosis. The oncotype
DX RS [29] is a commercially available assay (Genomic
Health, Redwood City, CA) that predicts recurrence in ER-
positive cases. It is a PCR-based assay on paraffin-embedded
Table 3
Correlation between molecular subtype and immohistochemical ER status
Subtype
N = 135
Basal
N = 36
(27%)
ERBB2
N = 17 (12.5%)
LuminalAa
N = 45 (33%)
LuminalAb
N = 21
(15.5%)
LuminalB
N = 3
(2%)
Normal-like N = 13
(10%)
ER-positive N = 81 3 (8%) 4 (23.5%) 43 (95.5%) 21 (100%) 3 (100%) 7 (53.8%)
ER-negative 
N = 54
33 (91.6%) 13 (76.4%) 2 (4.5%) 0 0 6 (46.2%)
P-value 4.5910-13 0.0029 9.6 10-11 4.9 10-6 NS NSBreast Cancer Research    Vol 11 No 2    Jacquemier et al.
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Table 4
Univariate analysis of 832 consecutive cases of breast carcinomas and 16 factors including classical histopronostic and 
immunohistochemical parameters
Variable NE (%) Classes N (%) Hazard Ratio [IC95] p-value
Hormonal therapy 0 (0%) no 361 (43%) 1 0.000209
yes 471 (57%) 0.558 [0.408–0.763]
Age 1 (0%) < 45 years 104 (13%) 1 0.673
>= 45 years 727 (87%) 1.1 [0.711–1.696]
< 45 104 (13%) 1 0.145
Tumor Size 7 (1%) < 25 mm 381 (46%) 1 < 0.0001
>= 25 mm 444 (54%) 2.47 [1.719–3.562]
Scarff-Bloom-Richardson grade 22 (3%) I 266 (33%) 1 < 0.0001
II–III 544 (67%) 3.69 [2.244–6.083]
VPI 4 (0%) Absent 536 (65%) 1 < 0.0001
present 292 (35%) 2.1 [1.519–2.897]
Lymph node invasion 16 (2%) N- 442 (54%) 1 < 0.0001
N+ 374 (46%) 2.61 [1.693–4.013]
AR 175 (21%) 0 220 (33%) 1 0.0122
> 0 437 (67%) 0.65 [0.463–0.913]
< 80 410 (62%) 1 0.00422
>= 80 247 (38%) 0.568 [0.383–0.841]
BCL2 201 (24%) 0 162 (26%) 1 0.000944
> 0 469 (74%) 0.548 [0.381–0.787]
CCND1 142 (17%) 0 284 (41%) 1 0.562
> 0 406 (59%) 0.905 [0.647–1.268]
ERBB2 123 (15%) 0 or 1 621 (88%) 1 0.209
2 or 3 88 (12%) 1.33 [0.852–2.071]
FOXA1 187 (22%) 0 40 (6%) 1 0.324
> 0 605 (94%) 1.43 [0.698–2.952]
GATA3 188 (23%) 0 247 (38%) 1 0.00024
> 0 397 (62%) 0.534 [0.38–0.75]
Ki67 171 (21%) < 20 560 (85%) 1 0.000748
>= 20 101 (15%) 1.96 [1.316–2.923]
P53 140 (17%) 0 525 (76%) 1 0.00095
> 0 167 (24%) 1.76 [1.253–2.47]
ER 79 (9%) 0 169 (22%) 1 0.000276
> 0 584 (78%) 0.54 [0.386–0.756]
PR 120 (14%) 0 263 (37%) 1 0.0875
> 0 449 (63%) 0.752 [0.542–1.044]
NE: Number of non evaluable or miss cases on tissu microarrays.Available online http://breast-cancer-research.com/content/11/2/R23
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tissue using 16 cancer-related genes and 5 controls. It was
validated on 668 node-negative cases in the National Surgical
Adjuvant Breast and Bowel Project (NSABP) trial receiving
tamoxifen only. The histopronostic grade and recurrence score
(RS) were significant. This RS was subsequently validated for
chemotherapy and tamoxifen in 645 patients from the NSABP-
14 [30]. Only four of the 16 genes are common with the fac-
tors we tested here (ER, PR, KI67 and BCL2). A more recent
series of 255 ER-positive cases established a signature vali-
dated on an independent set of 362 cases coming from differ-
ent institutions and treated by tamoxifen alone [31]. A total of
181 genes belonging to 13 clusters strongly prognostic (HR
= 3.26, P = 0.0002). These 13 cluster genes were the most
important factor in multivariate analysis.
Immunohistochemistry has been involved in the search for a
multiparametric score in ER-positive cases on a series of 257
ER-positive cases treated by tamoxifen; a multimarker model
was established from nine markers and five of them were
retained in a mathematic model: ER, PR, P53, ERBB2 and
MYC. This model was more prognostic than the Nottingham
prognostic index [4].
A previous study has looked at oestrogen-regulated genes in
the MCF7 breast cancer cell line treated by 17β–oestradiol
[32]. These genes were then used to develop an outcome pre-
dictor on a training set of 65 luminal breast cancers and then
validated on three independent published data sets. Interest-
ingly, two groups of low risk (expressing XBP1, FOXA1 and
PR) and high risk (expressing MYBL2 and CCNB2) were dis-
tinguished.
The study of a series of 140 cases used 23 antibodies and
identified a prognostic score for ER-positive breast cancer
without any notion of hormonal therapy [33]. Five factors were
retained by Cox analysis (P53, NDRG1, CEACAM5, SLC7A5
and HTF9c) but regression tree analysis retained six factors
(P53, PR, Ki67, NAT1, SLC7A5 and HTF9c). The best HR
was obtain by the Cox model (HR = 2.21, P = 0.0008).
P53 and Ki67 are the two factors common with our series.
This again underlines the impact of proliferation in luminal
cases. However, our analysis, with four factors, could be an
easier manner to study ER-positive cases.
The fact that in our series the patients all received adjuvant
tamoxifen stratified on chemotherapy suggests also that these
factors could be more than prognostic in cases receiving hor-
monal therapy.
Table 5
Significant parameters retained by Cox multivariate analysis in the estrogen receptor positive cases
N = 378 Coefficient HR IC95 p-value
Hormonal therapy no 1
yes -0.897 0.408 [0.257–0.647] 0.00014
Size < 25 mm 1
>= 25 mm 0.9 2.46 [1.449–4.175] 0.00085
Scarff-Bloom-Richardson grade I1
II–III 0.521 1.68 [0.805–3.522] 0.17
VPI no 1
yes 0.657 1.93 [1.213–3.068] 0.0055
Lymph node N- 1
N+ 0.68 1.97 [1.208–3.222] 0.0066
BCL2 < 160 1
>= 160 -0.613 0.542 [0.331–0.886] 0.015
Ki67 < 20 1
>= 20 0.641 1.9 [1.167–3.086] 0.0098
P53 01
> 0 0.369 1.45 [0.928–2.254] 0.1Breast Cancer Research    Vol 11 No 2    Jacquemier et al.
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Table 6
Correlation between the different subtypes and histopronostic and immunohistochemistry factors in ER-positive cases
Basal ERBB2 Luminal Aa Luminal Ab Luminal B Normal-like p-value
ER-positive
N = 84
3 4 43 (%)x 21(%)x 3 7 3 cases non evaluable
Grade I 1 0 14(32.5%) 0 05 4.710-6
Grade II 0 0 24(55.8%) 7(30%) 02
Grade III 2 4 5(11.6%) 14(66.6%) 30
VPI positive 0 1 20/42 (47.6%) 10/21
(47.6%)
31
Positive lymph nodes 1 2 26/43
(60.4%)
15/21
(71.4%)
22
AR positive 1 2 31/36(86%) 15/21(71.4%) 2 3
BCL2 positive 2 2 36/39 (92.3%) 14/15
(93%)
26 / 6
(100%)
CCND1
Positive
2 0 26/41 (63,4%) 13/19
(68%)
22 / 5
ERBB2 (2+/3+) 0 3 (3+) 3/43 (6.9%) 0 1(2+) 0
FOX A1 positive 1 3 38/39 (97.4%) 19/19
(100%
34 / 5
GATA3
Positive
0 1 29/36 (80.5%) 12/18
(66.6%)
34 / 5
Ki67 > 20% 1 0 2/40(5%) 5/18(27.7%) 00 0.02
P53 positive 2 2 8/42 (19%) 4/20 (20%) 1 0/6
PR
positive
0 0 37/43 (86%) 16/20 (80%) 2 5/6
Numbers in bold mean the percentage of positive available cases.
Figure 1
Influence of the molecular subtype on metastasis-free survival in ER-positive cases receiving hormonal therapy Influence of the molecular subtype on metastasis-free survival in ER-positive cases receiving hormonal therapy. Log-Rank test: P = 0.0402. ER = 
oestrogen receptor; MFS = metastasis-free survival.Available online http://breast-cancer-research.com/content/11/2/R23
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Table 7
Univariate analysis of ER-positive cases with adjuvant hormonal
Variable NE (%) Classes N (%) Hazard Ratio [IC95] p-value ×
Age 0 (0%) < 45 years 29 (8%) 1 0.964
>= 45 years 355 (92%) 1.02 [0.401–2.605]
< 45 29 (8%) 1 0.315
45–60 155 (40%) 0.834 [0.312–2.226]
> 60 200 (52%) 1.32 [0.493–3.522]
Tumoral size 2 (1%) < 25 mm 141 (37%) 1 0.0222
>= 25 mm 241 (63%) 2.16 [1.1–4.23]
Scarff-Bloom-Richardson grade 2 (1%) I 141 (37%) 1 0.000487
II–III 241 (63%) 4.1 [1.74–9.644]
VPI 3 (1%) absent 237 (62%) 1 0.00363
present 144 (38%) 2.36 [1.305–4.268]
N 3 (1%) N- 174 (46%) 1 0.0495
N+ 207 (54%) 2.22 [1–4.921]
N < 3 288 (76%) 1 < 0.0001
N >= 3 93 (24%) 3.81 [2.113–6.883]
AR 66 (17%) 0 74 (23%) 1 0.306
> 0 244 (77%) 0.712 [0.371–1.369]
BCL2 66 (17%) 0 38 (12%) 1 0.0676
> 0 280 (88%) 0.492 [0.226–1.069]
CCND1 47 (12%) 0 97 (29%) 1 0.971
> 0 240 (71%) 1.01 [0.542–1.886]
ERBB2 36 (9%) 1 or 2 319 (92%) 1 0.558
2 or 3 29 (8%) 1.32 [0.519–3.359]
FOXA1 78 (20%) 0 3 (1%) 1 0.406
> 0 303 (99%) 9220000 [0-Inf]
GATA3 66 (17%) 0 70 (22%) 1 0.0952
> 0 248 (78%) 0.599 [0.326–1.1]
Ki67 60 (16%) < 20 299 (92%) 1 0.000304
>= 20 25 (8%) 3.58 [1.709–7.488]
P53 55 (14%) 0 272 (83%) 1 < 0001
> 0 57 (17%) 3.13 [1.745–5.601]
ER 0 (0%) < 120 153 (40%) 1 0.227
>= 120 231 (60%) 0.71 [0.406–1.24]
PR 44 (11%) 0 76 (22%) 1 0.941
> 0 264 (78%) 0.975 [0.499–1.904]
NE: non evaluable cases on Tissu-micro arrays. × Logrank test stratified on chemotherapy.Breast Cancer Research    Vol 11 No 2    Jacquemier et al.
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Conclusions
Our study of immunohistochemistry factors in luminal breast
cancers demonstrates the interest to combine prognostic
markers to improve the therapeutic choice.
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